Table 3.

Results of various targeted therapy phase II trials in recurrent glioblastoma

ReferenceDosenORR (CR + PR), %Disease control (CR + PR + SD), %Median PFS (mo)6-month PFS (%)Median OS (mo)
Temsirolimus
    Chang et al. (47)170–250 mg weekly435472.33
    Galanis et al. (17)250 mg weekly650NA2.384
Imatinib
    Raymond et al. (15)*600–800 mg514352.316NA
    Wen et al. (56)600–800 mg34624NA3NA
Imatinib + hydroxyurea
    Dresemann (57)3020572.5324.8
    Reardon et al. (58)Imatinib, 400–1,000 g; hydroxyurea, 500 mg3093.62712
Vatalanib
    Conrad et al. (phase I/II; ref. 63)*150–2,000 mg47456NANANA
Vatalanib + TMZ or CCNU
    Reardon et al. (phase I/II; ref. 64)*500–1,500 mg (TMZ, 200 mg/m2; CCNU, 130 mg/m2)518534 (TMZ); 2.5 (CCNU)NANA
Bevacizumab + irinotecan
    Vredenburgh et al. (74)10 mg/kg (irinotecan, 125 mg/m2)23619653010
Enzastaurin
    Fine et al. (78)*500–900 mg632227NANANA
  • Abbreviations: TMZ, temozolomide; CCNU, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea.

  • * Preliminary results presented in the form of abstract.